Abdominal adipose tissue fibrosis as an obesity biomarker in clinical practice

Simple item page
dc.contributor.authorMartínez Subirà, Mariona
dc.contributor.authorPallares, Judit
dc.contributor.authorSalinas-Roca, Blanca
dc.contributor.authorBuenaventura-Collazos, Daisy
dc.contributor.authorHernández, Cristina
dc.contributor.authorSimó, Rafael
dc.contributor.authorLecube, Albert
dc.date.accessioned2026-06-26T08:54:39Z
dc.date.available2026-06-26T08:54:39Z
dc.date.issued2026
dc.description.abstractIntroduction The aims of the study were to describe a biopsy procedure to obtain subcutaneous adipose tissue (SAT) samples for fibrosis assessment in patients with adipose-based chronic disease (ABCD) and to explore potential associations between SAT fibrosis and comorbidities. Methods Single-center, cross-sectional study conducted at the Arnau de Vilanova University Hospital (Lleida, Spain) between January and December 2024. We included patients aged 18–65 years attending their first appointment in the Obesity Unit. Between-group comparisons were performed using Student’s t-test for continuous variables and chi-square tests for categorical variables, and correlations were assessed using Spearman’s rank correlation coefficient. Results 58 patients were recruited and 50 were included in the final analysis. Most were female (76.0%), with a mean age of 47.1 years (SD: 10.8), and a mean BMI of 46.3 kg/m2 (SD: 5.0). The biopsy technique evolved over time, reducing the procedure duration from 55 min to under 10 min without any adverse events. SAT fibrosis was observed in 10 patients (20.0%), who showed a higher prevalence of type 2 diabetes (50.0% vs. 15.0%, p = 0.017), significantly higher aspartate transaminase and gamma-glutamyl transferase, and elevated signs of liver fibrosis. Conclusion SAT fibrosis was associated with ABCD comorbidities and could serve as a tool for risk stratification beyond traditional indicators.
dc.description.sponsorshipThis research has been funded by the Instituto de Salud Carlos III (ISCIII) through project PI24/00852 and co-funded by the European Union. Other projects related to this research are PI20/01806, PI21/00462, and PMP22/00073, as well as a and a research grant from Pfizer S.L.U.
dc.identifier.doihttps://doi.org/10.1159/000550517
dc.identifier.urihttps://hdl.handle.net/10459.1/470676
dc.language.isoeng
dc.publisherKarger
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1159/000550517
dc.relation.ispartofObesity Facts, 2026. In press
dc.rightscc-by-nc (c) Martínez et al., 2026
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectBiopsy
dc.subjectSubcutaneous adipose tissue
dc.subjectAdiposity-based chronic disease
dc.subjectDiabetes mellitus
dc.titleAbdominal adipose tissue fibrosis as an obesity biomarker in clinical practice
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
obefac_a2026p1.pdf
Size:
2.17 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
639 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Articles publicats (Tecnologia, Enginyeria i Ciència dels Aliments)